New Approaches in the Development of a Vaccine for Mucosal Candidiasis: Progress and Challenges
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The commensal fungus Candida albicans causes mucosal candidiasis in the rapidly expanding number of immunocompromised patients. Mucosal candidiasis includes oropharyngeal, esophageal, gastrointestinal, and vaginal infections. Vulvovaginal candidiasis (VVC) and antimycotic-refractory recurrent VVC is a frequent problem in healthy childbearing women. Both these mucosal infections can affect the quality of life and finding new therapeutical and preventive approaches is a challenge. A vaccine against candidal infections would be a new important tool to prevent and/or cure mucosal candidiasis and would be of benefit to many patients. Several Candida antigens have been proposed as vaccine candidates including cell wall components and virulence factors. Here we discuss the recent progress and problems associated with vaccination against mucosal candidiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Candida albicans Secreted Aspartyl Proteinases in Virulence and Pathogenesis
Naglik, J. R., Challacombe, S. J., & Hube, B. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.3.400-428.2003 · Cited by 1,179 · cited 1×
“One attempt to develop a mucosal vaccination was by using an aspartyl proteinase (Sap2), a very well known enzyme belonging to a family of virulence factors of C. albicans (Naglik et al., 2003).”
BackgroundConti, H. R., Shen, F., Nayyar, N., Stocum, E., Sun, J. N., Lindemann, M. J., Ho, A. W., Hai, J. H., Yu, J. J., Jung, J. W., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081463 · Cited by 1,024
An integrated model of the recognition of Candida albicans by the innate immune system
Netea, M. G., Brown, G. D., Kullberg, B. J., & Gow, N. A. R. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1815 · Cited by 946 · cited 3×
“…capable of distinguishing its different forms of growth (Moyes et al., 2010), however the relative role of pattern recognition receptors (PRRs) in ECs is still largely unclear, despite the intensive research in PRRmediated interaction of C. albicans with myeloid cells (Netea et al., 2006, 2008).”
BackgroundInfluentialA novel glyco-conjugate vaccine against fungal pathogens
Torosantucci, A., Bromuro, C., Chiani, P., De Bernardis, F., Berti, F., Galli, C., Norelli, F., Bellucci, C., Polonelli, L., Costantino, P., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050749 · Cited by 442
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00192-2 · Cited by 424 · cited 3×
“The associated mortality depends on host conditions, and ranges between 30 and 50% (Pfaller et al., 1998b; Kibbler et al., 2003).”
BackgroundCandida albicans Als3, a multifunctional adhesin and invasin
Liu, Y., & Filler, S. G. (2011) · Eukaryotic Cell · doi:10.1128/ec.00279-10 · Cited by 354 · cited 1×
“Human trials with the rAls3-N vaccine are in final preparation (Liu and Filler, 2011).”
Zakikhany, K., Naglik, J. R., Schmidt-Westhausen, A., Holland, G., Schaller, M., & Hube, B. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2007.01009.x · Cited by 288
Rhee, S. H., Im, E., Riegler, M., Kokkotou, E., O'Brien, M., & Pothoulakis, C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502174102 · Cited by 229
Management and outcome of bloodstream infections due to Candida species in England and Wales
Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holliman, R. E., Johnson, E. M., Perry, J. D., Sullivan, D. J., & Wilson, J. A. (2003) · Journal of Hospital Infection · doi:10.1016/s0195-6701(03)00085-9 · Cited by 187 · cited 2×
“The associated mortality depends on host conditions, and ranges between 30 and 50% (Pfaller et al., 1998b; Kibbler et al., 2003).”
BackgroundInfluential
Cited by
Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis
Scorzoni, L., de Paula e Silva, A. C. A., Marcos, C. M., Assato, P. A., de Melo, W. C. M. A., de Oliveira, H. C., Costa-Orlandi, C. B., Mendes-Giannini, M. J. S., & Fusco-Almeida, A. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00036 · Cited by 418
“Oral administration of these cells could elicit an immune response and aid the survival of mice challenged with C. albicans (Vecchiarelli et al., 2012; Shibasaki et al., 2013; Shahid, 2016).”
BackgroundGuideline: Vulvovaginal Candidosis (AWMF 015/072, Level S2k)
Farr, A., Effendy, I., Frey Tirri, B., Hof, H., Mayser, P., Petricevic, L., Ruhnke, M., Schaller, M., Schaefer, A. P. A., Sustr, V., et al. (2021) · Mycoses · doi:10.1111/myc.13248 · Cited by 184
Guideline: Vulvovaginal Candidosis (AWMF 015/072), S2k (Excluding Chronic Mucocutaneous Candidosis)
Mendling, W. (2015) · Mycoses · doi:10.1111/myc.12292 · Cited by 117
Metadata
- Authors
- Vecchiarelli, A., Pericolini, E., Gabrielli, E., & Pietrella, D.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 3
- Pages
- 294-294
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W2038822048
- Cited by
- 43
- References
- 14
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Approaches in the Development of a Vaccine for Mucosal Candidiasis: Progress and Challenges. https://app.cochat.ai/papers/10.3389/fmicb.2012.00294
- The paper
- Vecchiarelli, A., Pericolini, E., Gabrielli, E., & Pietrella, D. (2012). New Approaches in the Development of a Vaccine for Mucosal Candidiasis: Progress and Challenges. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2012.00294
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.